Research To Practice | Oncology Videos

Featuring perspectives from Dr Sarah B Goldberg, Dr Brad S Kahl, Dr Sagar Lonial, Dr Joyce O'Shaughnessy, Dr Noopur Raje, Dr Joshua K Sabari, Dr Matthew R Smith, Dr Sonali M Smith, Dr Sandy Srinivas and Dr Seth Wander, including the following topics: Introduction (0:00) Hormone Receptor-Positive Breast Cancer — Dr O'Shaughnessy (10:45) Management of Relapsed/Refractory HR-Positive Metastatic Breas...

What Clinicians Want to Know About the Current and Future Role of EZH1/2 Inhibitors in the Care of Patients with Lymphoma — Gilles Salles, MD, PhD CME information and select publications

Featuring an interview with Dr Gilles Salles, including the following topics: Epigenetic modifications and the role of EZH2 in the pathobiology of follicular lymphoma (FL) (0:00) Natural history of FL and current treatment landscape in the first-line setting (5:20) Testing approaches for the detection of EZH2 mutations (14:37) Mechanism of action of the EZH inhibitors tazemetostat and valemetostat...

Featuring an interview with Dr Stephen V Liu , including the following topics: Management of localized non-small cell lung cancer (NSCLC) (0:00) First-line treatment of advanced NSCLC (10:53) Targeted therapy for patients with NSCLC and actionable genomic alterations (30:24) Recent FDA approvals for NSCLC (37:49) Recent advances in small cell lung cancer (47:14) Lurbinectidin in combination with a...

Featuring perspectives from Dr Tanios Bekaii-Saab and Dr Philip A Philip, including the following topics: Introduction (0:00) Colorectal Cancer, Anal Cancer and Pancreatic Cancer — Dr Philip (1:56) Gastroesophageal Cancers, Hepatocellular Cancer and Biliary Tract Cancers — Dr Bekaii-Saab (41:48) CME information and select publications

Featuring perspectives from Prof Francois-Clement Bidard and Dr Kevin Kalinsky, including the following topics: Introduction: Confronting Metastatic Breast Cancer (mBC) (0:00) Mechanisms of Resistance to Endocrine Therapy in HR-Positive mBC; Use of Oral Selective Estrogen Receptor Degraders (SERDs) — Dr Kalinsky (13:18) Ongoing Evaluation of Early Therapeutic Switching for HR-Positive mBC Harborin...

Practical Perspectives: Optimizing the Role of BTK Inhibitors in the Management of Mantle Cell Lymphoma | Faculty Presentation — Michael Wang, MD CME information and select publications.

Featuring perspectives from Dr Tycel Phillips and Dr Michael Wang, including the following topics: Introduction: Interface Between Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma (0:00) Key Datasets — Overview and First-Line Therapy (7:16) Faculty Case Presentations — Dr Phillips (27:03) Key Datasets — Relapsed/Refractory Disease (35:40) Faculty Case Presentations — Dr Wang (48:06) CME infor...

Featuring a slide presentation and related discussion from Dr Erika Hamilton, including the following topics: Targeted therapies for ER-positive breast cancer (0:00) Clinical data with oral selective estrogen receptor degraders (2:13) Biological rationale for and mechanism of action of proteolysis-targeting chimeras (PROTACs) (7:07) Emerging data with PROTACs for ER-positive advanced breast cancer...

Featuring an interview with Dr Erika Hamilton , including the following topics: Pathophysiology and pharmacology of ER-positive breast cancer treatment (0:00) Clinical evidence available with oral selective estrogen receptor degraders (3:46) Mechanism of action of proteolysis-targeting chimeras (PROTACs) (13:22) PROTACs currently in clinical development (16:39) Case: A woman in her late 30s with H...

Practical Perspectives: Current Management of Chronic Myeloid Leukemia | Faculty Presentation — Jorge Cortes, MD   CME information and select publications

Featuring perspectives from Dr Bhavana (Tina) Bhatnagar, Dr Amanda Blackmon, Dr Jorge Cortes, Dr Michael J Mauro and Dr Neil P Shah, including the following topics: Recently presented data affecting the treatment of newly diagnosed chronic myeloid leukemia (CML) (0:00) Case: A man in his mid 40s with newly diagnosed CML with tyrosine kinase inhibitor (TKI) tolerability issues but a good response (...

Featuring perspectives from Dr Jacob Sands, including the following topics: Introduction: A man in his mid 60s with a lung nodule on lung cancer screening (0:00) Current and Future Management of Small Cell Lung Cancer (15:42) CME information and select publications

Featuring perspectives from Dr Thierry Alcindor and Dr Mrinal Gounder, including the following topics: Introduction: Biology and Clinical Presentation (0:00) Case: A man in his mid 60s with desmoid fibromatosis — Dr Alcindor (12:36) Tyrosine Kinase Inhibitors (24:51) Gamma Secretase Inhibitors (31:02) Case: A woman in her early 40s with desmoid tumor treated with a gamma secretase inhibitor on a c...

Featuring a slide presentation and related discussion from Dr Steven Horwitz, including the following topics: Front-line management of peripheral T-cell lymphomas (PCTLs) (0:00) Dose-intensified chemotherapy in combination with brentuximab vedotin for PTCL (9:59) Role of CD30 for PTCLs (14:36) Management of relapsed PTCL (20:40) CME information and select publications

Featuring an interview with Dr Steven Horwitz , including the following topics: Overview of peripheral T-cell lymphomas (PTCLs) (0:00) Efficacy and safety of brentuximab vedotin in the management of treatment-naïve and relapsed PTCLs (9:57) Emerging therapeutic strategies for PTCLs (19:48) Case: A man in his early 50s with CD30-positive anaplastic large cell lymphoma who experienced complete respo...

Featuring perspectives from Dr Edward B Garon and Dr Luis Paz-Ares, including the following topics: Introduction: Ivonescimab (0:00) First-Line Therapy for Metastatic Non-Small Cell Lung Cancer (NSCLC) without a Targetable Tumor Mutation — Dr Garon (11:47) Promising Therapeutic Strategies for Patients with Progressive Metastatic NSCLC — Dr Paz-Ares (42:01) CME information and select publications

Featuring perspectives from Dr Matthew S Davids, including the following topics: Introduction: Is Chronic Lymphocytic Leukemia (CLL) the New Chronic Myeloid Leukemia? Cases We Didn't Hear About Last Week (0:00) Case: A man in his early 70s with IGHV-unmutated CLL (trisomy 12, del[17p]) receives ibrutinib for several years and is switched to acalabrutinib to lower the risk of cardiotoxicity — Warre...

Featuring perspectives from Dr Christopher Flowers, Prof Grzegorz S Nowakowski and Dr Laurie H Sehn, moderated by Dr Flowers, including the following topics: Introduction (0:00) Front-Line Management of Diffuse Large B-Cell Lymphoma (DLBCL) — Dr Sehn (1:56) Case: A woman in her late 40s with epidural DLBCL and a compression fracture (Dr Flowers) (12:45) Case: A woman in her late teens with primary...

Featuring perspectives from Dr Ibiayi Dagogo-Jack and Dr Corey J Langer, including the following topics: Introduction: A Model for Targeted Treatment in Non-Small Cell Lung Cancer (NSCLC) (0:00) NSCLC with ALK, ROS1 and NTRK Rearrangements — Dr Langer (9:10) Current and Future Treatment of Metastatic NSCLC with RET, MET, HER2 and KRAS Alterations — Dr Dagogo-Jack (34:22) CME information and select...

Featuring perspectives from Dr Joshua Brody, Dr Matthew Lunning and Dr Jason Westin, moderated by Dr Lunning, including the following topics: Introduction (0:00) Integration of Chimeric Antigen Receptor (CAR) T-Cell Therapy into the Management of Diffuse Large B-Cell Lymphoma — Dr Westin (1:34) Current Role of CAR T-Cell Therapy for Other B-Cell Lymphomas — Dr Lunning (21:17) Tolerability and Othe...

Featuring perspectives from Dr Joshua K Sabari and Dr Helena Yu, including the following topics: Introduction: Checkpoint Inhibitors and Lung Cancer with an EGFR Mutation (0:00) Current Management of Metastatic Non-Small Cell Lung Cancer (NSCLC) with EGFR Mutations — Dr Sabari (5:39) Novel Therapeutic Approaches for NSCLC Harboring EGFR Mutations — Dr Yu (28:21) CME information and select publicat...

Featuring a slide presentation and related discussion from Dr Tiffany A Traina, including the following topics: Extended follow-up with pembrolizumab/chemotherapy for patients with previously untreated PD-L1-positive metastatic triple-negative breast cancer (mTNBC) (0:00) ASCENT trial: Survival advantage with sacituzumab govitecan versus physician's choice of chemotherapy for patients with relapse...

Featuring an interview with Dr Tiffany A Traina, including the following topics: Choice of chemotherapy to combine with first-line pembrolizumab for metastatic triple-negative breast cancer (mTNBC) (0:00) Ongoing investigations of androgen receptor-targeting agents for metastatic breast cancer (mBC) (8:37) Efficacy and CNS activity of sacituzumab govitecan for mTNBC; monitoring and management of t...

Featuring slide presentations and related discussion from Dr Lipika Goyal, Dr James J Harding, Dr Milind Javle and Dr Robin K (Katie) Kelley, including the following topics: Current Role of Immunotherapeutic Strategies for Advanced Biliary Tract Cancers (BTCs) — Dr Kelley (0:00) Case: A man in his late 60s with advanced distal cholangiocarcinoma treated with the TOPAZ-1 regimen (13:27) Case: A wom...